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This article contains data related to the research article entitled
“Altered relation of the renin-aldosterone system and vasoactive
peptides in type 2 diabetes: the KORA F4 study” (Then et al., 2016)
[1] and describes the association of the aldosterone to renin ratio
with midregional-pro atrial natriuretic peptide (MR-proANP) and
midregional-pro adrenomedullin (MR-proADM) in 1261 partici-
pants from the KORA F4 cohort.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
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Dubject area Diabetes
ore speciﬁc sub-
ject areaCardiovascular disease in diabetesype of data Tables
ow data was
acquiredCohort studyata format Analyzed
xperimental
factorsPlasma samples were obtained from 1261 participants of the population-based
KORA F4 cohort after an overnight fast.xperimental
featuresPlasma MR-proANP, MR-proADM, renin and aldosterone were measured. Linear
regression models were used to assess the association between MR-proANP/MR-
proADM and aldosterone-renin-ratio.ata source
locationCooperative Health Research in the Region of Augsburg, Southern Germanyata accessibility The data is with this articleD
Value of the data
 The aldosterone to renin ratio was only associated with MR-proANP and MR-proADM in subjects
without diabetes or prediabetes.
 The current data may be helpful for the planning of further clinical and/or preclinical research
aiming to work out the differences in vasoactive hormones in subjects with and without diabetes.
 Vasoactive prohormones, including MR-proANP and MR-proADM, are interesting candidates for
future research focusing on the pathophysiological links between diabetes and cardiovascular
disease.1. Data
Two Tables are presented showing the associations of vasoactive prohormones with the aldos-
terone to renin ratio (ARR) in subjects with and without diabetes type 2 or prediabetes in a
population-based cohort. Table 1 displays the association of the ARR with MR-proANP and Table 2
shows the relation of ARR and MR-proADM.2. Experimental design, materials and methods
Recruitment of study participants, laboratory measurements and statistical analyses are described
in detail elsewhere [1]. Brieﬂy, the population-based KORA (Cooperative Health Research in the
Region of Augsburg, southern Germany) F4 cohort includes 3080 participants recruited between 2006
and 2008. From this cohort, a sample of 1596 subjects was randomly selected for plasma MR-proANP
and MR-proADM measurements. All variables required for the currently described analyses were
available in 1261 study participants. ARR was calculated by dividing plasma aldosterone levels (ng/l)
by plasma renin levels (ng/l).
Table 1
Association of ARR (logarithmized) and MR-proANP (linear regression). Bold: po0.05.
MR-proANP
Q4 vs Q1-Q3
p-
value
MR-proANP
Q4 vs Q1
p-value MR-proANP metric p-value
Regression coefﬁcient
(95% CI)
Regression coefﬁcient
(95% CI)
Regression coefﬁcient
(95% CI)
No adjustment
All subjects 0.030 (0.119 to 0.179) 0.694 0.214 (0.020–0.408) 0.031 0.00071 (0.00047 to
0.00189)
0.237
Prediabetes 0.299 (0.081 to
0.679)
0.123 0.143 (0.31–0.597) 0.532 0.00284 (0.00008 to
0.00575)
0.056
Diabetes 0.344 (0.88 to
0.192)
0.206 0.494 (1.193 to
0.204)
0.163 0.00222 (0.00578
to 0.00134)
0.219
No diabetes/
prediabetes
0.163 (0.005 to
0.331)
0.057 0.407 (0.184–0.629) o0.001 0.00131 (0.00009 to
0.00271)
0.066
Adjusted for age and sex
All subjects 0.039 (0.134 to 0.211) 0.661 0.289 (0.014 to
0.593)
0.062 0.00076 (0.00059 to
0.00211)
0.267
Prediabetes 0.322 (0.099 to
0.744)
0.133 0.111 (0.754 to
0.532)
0.732 0.00317 (0.00013 to
0.00648)
0.060
Diabetes 0.425 (1.015 to
0.164)
0.156 0.589 (1.445 to
0.266)
0.173 0.00274 (0.00669 to
0.00121)
0.173
No diabetes/
prediabetes
0.111 (0.088 to 0.309) 0.274 0.477 (0.133–0.821) 0.007 0.00057 (0.00103 to
0.00218)
0.484
Adjusted for age, sex and BMI
All subjects 0.025 (0.146 to 0.197) 0.771 0.2851 (0.012 to
0.582)
0.060 0.00066 (0.00068 to
0.00200)
0.336
Prediabetes 0.301 (0.120 to
0.722)
0.160 0.144 (0.790 to
0.502)
0.660 0.00288 (0.00044 to
0.00619)
0.090
Diabetes 0.423 (1.022 to
0.177)
0.165 0.504 (1.416 to
0.408)
0.273 0.00271 (0.0067 to
0.00128)
0.182
No diabetes/
prediabetes
0.098 (0.100 to
0.296)
0.332 0.444 (0.106–0.781) 0.010 0.00057 (0.00103 to
0.00217)
0.488
Multivariable adjustmenta
All subjects 0.178 (0.003–0.354) 0.046 0.375 (0.068–0.681) 0.017 0.00230 (0.00088–
0.00372)
0.002
Prediabetes 0.528 (0.110–0.946) 0.013 0.035 (0.686–0.756) 0.924 0.00661 (0.00316–
0.01006)
o0.001
Diabetes 0.104 (0.775 to
0.567)
0.759 0.152 (1.319–1.014) 0.794 0.00032 (0.00422 to
0.00486)
0.890
No diabetes/
prediabetes
0.196 (0.011 to 0.403) 0.063 0.532 (0.180–0.884) 0.003 0.00142 (0.0003 to
0.00313)
0.106
a Adjustment for age, sex, BMI, hypertension (yes/no), HDL cholesterol (continuous), LDL cholesterol (continuous), trigly-
cerides (continuous), former myocardial infarction or stroke, smoking behaviour (active/former/never), alcohol consumption
(never/moderate/high), physical activity (high/low), hsCRP, eGFR, statins, NSAID, beta-blockers, angiotensin converting enzyme
inhibitors and angiotensin 1 receptor antagonists.
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Table 2
Association of ARR (logarithmized) and MR-proADM (linear regression). Bold: po0.05.
MR-proADM
Q4 vs Q1-Q3
p-value MR-proADM
Q4 vs Q1
p-
value
MR-proADM metric p-value
Regression coefﬁcient
(95% CI)
Regression coefﬁcient
(95% CI)
Regression coefﬁcient
(95% CI)
No adjustment
All subjects 0.221 (0.369 to
0.074)
0.003 0.115 (0.330 to
0.101)
0.297 0.818 (1.196 to
0.440)
o0.001
Prediabetes 0.036 (0.366 to
0.437)
0.861 0.094 (0.548 to
0.36)
0.682 0.438 (1.566 to
0.689)
0.444
Diabetes 0.409 (0.894 to –
0.077)
0.098 0.344 (1.091 to
0.403)
0.361 1.086 (2.197 to
0.026)
0.055
No diabetes/
prediabetes
0.116 (0.312 to
0.081)
0.248 0.026 (0.216 to
0.269)
0.831 0.512 (0.986 to
0.039)
0.034
Adjusted for age and sex
All subjects 0.326 (0.492 to
0.159)
o0.001 0.173 (0.513 to
0.166)
0.316 1.213 (1.659
to 0.768)
o0.001
Prediabetes 0.037 (0.458 to
0.384)
0.862 0.250 (0.786 to
0.285)
0.355 0.954 (2.220 to
0.312)
0.139
Diabetes 0.469 (0.981 to
0.043)
0.072 0.413 (1.296 to
0.470)
0.353 1.366 (2.593
to 0.138)
0.029
No diabetes/
prediabetes
0.268 (0.481 to
0.056)
0.013 0.168 (0.541 to
0.205)
0.377 0.961 (1.501
to 0.421)
o0.001
Adjusted for age, sex and BMI
All subjects 0.239 (0.412 to
0.066)
0.007 0.024 (0.351 to
0.399)
0.900 0.979 (1.453
to 0.504)
o0.001
Prediabetes 0.02 (0.404 to 0.443) 0.927 0.137 (0.694 to
0.419)
0.625 0.737 (2.034 to
0.561)
0.264
Diabetes 0.509 (1.06 to
0.041)
0.070 0.368 (1.383 to
0.646)
0.471 1.459 (2.759 to
0.159)
0.028
No diabetes/
prediabetes
0.196 (0.416 to
0.024)
0.080 0.020 (0.392 to
0.432)
0.923 0.759 (1.337
to 0.182)
0.010
Multivariable adjustmenta
All subjects 0.070 (0.252 to
0.113)
0.455 0.189 (0.204 to
0.582)
0.344 0.526 (1.061
to 0.010)
0.054
Prediabetes 0.176 (0.263 to 0.615) 0.431 0.010 (0.656 to
0.675)
0.977 0.573 (0.925 to
2.071)
0.451
Diabetes 0.173 (0.800 to
0.453)
0.585 0.032 (1.160 to 1.225) 0.957 0.527 (2.132 to
1.077)
0.516
No diabetes/
prediabetes
0.118 (0.352 to
0.115)
0.319 0.030 (0.414 to 0.475) 0.894 0.660 (1.309
to 0.011)
0.046
a Adjustment for age, sex, BMI, hypertension (yes/no), HDL cholesterol (continuous), LDL cholesterol (continuous), trigly-
cerides (continuous), former myocardial infarction or stroke, smoking behaviour (active/former/never), alcohol consumption
(never/moderate/high), physical activity (high/low), hsCRP, eGFR, statins, NSAID, beta-blockers, angiotensin converting enzyme
inhibitors and angiotensin 1 receptor antagonists.
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